Influence of low molecular weight heparin compared to conventional heparin for anticoagulation during haemodialysis on low density lipoprotein subclasses

Nephrology Dialysis Transplantation

Volumn 17, Issue 12, 2002, Pages 2231-2238

  Wiemer, Jörg ^a   Winkler, Karl ^b   Baumstark, Manfred ^b   März, Winfried ^b   Scherberich, Jürgen E ^a  

^a Hospital Mu nchen Harlaching   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Atherogenic lipoprotein phenotype; Haemodialysis; LDL subfractions; Low molecular weight heparin

Indexed keywords

ANABOLIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN; APOLIPOPROTEIN A; APOLIPOPROTEIN B; APOLIPOPROTEIN C; APOLIPOPROTEIN E; CALCIUM; CALCIUM ANTAGONIST; CHOLESTEROL; DALTEPARIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; ESTROGEN; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW MOLECULAR WEIGHT HEPARIN; MULTIVITAMIN; PHOSPHATE BINDING AGENT; PROGESTERONE; SEVELAMER; TESTOSTERONE; THYROID HORMONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTICOAGULANT AGENT;

ADULT; ANTICOAGULATION; ARTICLE; ATHEROGENESIS; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; FEMALE; HEMODIALYSIS; HUMAN; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; MALE; OUTPATIENT; PILOT STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ISOLATION; TRIACYLGLYCEROL BLOOD LEVEL; TURBIDIMETRY; ULTRACENTRIFUGATION; BLOOD; CLASSIFICATION; RENAL REPLACEMENT THERAPY;

ANTICOAGULANTS; APOLIPOPROTEINS B; DALTEPARIN; FEMALE; HEPARIN; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS, LDL; MALE; PILOT PROJECTS; RENAL DIALYSIS; TRIGLYCERIDES;

EID: 1842863747     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.12.2231     Document Type: Article

References (27)

1. Levey AS, Beto JA, Parfrey PS et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 1998; 32: 85-90
2. Wanner C. Importance of hyperlipidaemia and therapy in renal patients. Nephrol Dial Transplant 2000; 15 [Suppl 5]: 92-96
3. Oda H, Keane WF. Lipid abnormalities in end-stage renal disease. Nephrol Dial Transplant 1998; 13 [Suppl 1]: 45-49
4. Attman P-O, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21: 573-592
5. O'Neal D, Lee P, Murphy B, Best J. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am J Kidney Dis 1996; 27: 84-91
6. Rajman I, Harper L, McPake D, Kendall MJ, Wheeler DC. Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transplant 1998; 13: 2281-2287
7. Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res 1991; 32: 1741-1753
8. Dejager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 1993; 34: 295-308
9. Nordestgaard BG, Nielsen LB. Atherosclerosis and arterial influx of lipoproteins. Curr Opin Lipidol 1994; 4: 252-257
10. Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994; 5: 339-349
11. Arnadottir M. Pathogenesis of dyslipoproteinemia in renal insufficiency. The role of lipoprotein lipase and hepatic lipase. Scand J Clin Lab Invest 1997; 57: 1-11
12. Campos H, Dreon DM, Krauss RM. Associations of hepatic and lipoprotein lipase activities with changes in dietary composition and low density lipoprotein subclasses. J Lipid Res 1995; 36: 462-472
13. Engelberg H. Actions of heparin in the atherosclerotic process. Pharmacol Rev 1996; 42: 327-352
14. Griffin BA, Packard J. Metabolism of VLDL and LDL subclasses. Curr Opin Lipidol 1994; 5: 200-206
15. Arnadottir M, Kurkus J, Nilsson-Ehle P. Different types of heparin in hemodialysis: long-term effects on post-heparin lipases. Scand J Clin Lab Invest 1994; 54: 515-521
16. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human plasma. J Clin Invest 1955; 34: 1345-1359
17. Baumstark MW, Kreutz W, Berg A, Frey I, Keul J. Structure of human low-density lipoprotein subtractions, determined by x-ray small-angle scattering. Biochim Biophys Acta 1990; 1037: 48-57
18. Winkler K, Wetzka B, Hoffmann MW et al. Low density lipoprotein (LDL) subfractions during pregnancy: accumulation of buoyant LDL with advancing gestation. J Clin Endocrinol Metab 2000; 85: 4543-4550
19. Stenvinkel P. Low molecular weight heparin-does it favourably affect lipid levels? Nephrol Dial Transplant 1995; 10: 16-18
20. Wiemer J, Scherberich JE. Wenn bei der Dialyse die Lipide steigen. MMW-Fortschr Med 1999; 141: 729-732
21. Kronenberg F, Konig P, Lhotta K, Steinmetz A, Diplinger H. Low molecular weight heparin does not necessarily reduce lipids and lipoproteins in hemodialysis patients. Clin Nephrol 1995; 43: 399-404
22. Kronenberg F, Konig P, Neyer U et al. Influence of various heparin preparations on lipoproteins in hemodialysis patients: A multicenter study. Thromb Haemost 1995; 74: 1025-1028
23. Olivecrona T, Bengtsson-Olivecrona G. Lipoprotein lipase and hepatic lipase. Curr Opin Lipidol 1990; 1: 222-230
24. Goldberg IJ, Le NA, Ginsberg HN, Krauss RM, Lindgren FT. Lipoprotein metabolism during acute inhibition of lipoprotein lipase in the cynomolgus monkey. J Clin Invest 1988; 81: 561-568
25. Zambon A, Deeb SS, Hokanson JE, Brown BG, Brunzell JD. Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol. Arterioscler Thromb Vasc Biol 1998; 18: 1723-1729
26. Goldberg IJ, Mazlen RG, Rubenstein A et al. Lipoprotein metabolism during acute inhibition of hepatic triglyceride lipase in the cynomolgus monkey. Metabolism 1985; 34: 832-835
27. Frost RJA, Otto C, Geiss HC, Schwandt P, Parhofer KG. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol 2001; 87: 44-48